Avenue Therapeutics Announces Reverse Stock Split and Provides Regulatory Update for IV Tramadol Including Receipt of Type A Meeting Minutes from the FDA

September 22, 2022

https://www.globenewswire.com/news-release/2022/09/22/2521481/0/en/Avenue-Therapeutics-Announces-Reverse-Stock-Split-and-Provides-Regulatory-Update-for-IV-Tramadol-Including-Receipt-of-Type-A-Meeting-Minutes-from-the-FDA.html

NEW YORK, Sept. 22, 2022 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq:ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, today announced that it will effect a 1-for-15 reverse split of its common stock, which will be effective for trading purposes on the Nasdaq Capital Market as of the commencement of trading on September 23, 2022, and also provided a regulatory update related to its intravenous (“IV”) Tramadol product candidate.

Read more at globenewswire.com

Related news for (ATXI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.